Acadian Asset Management LLC raised its position in shares of Minerva Neurosciences, Inc. (NASDAQ:NERV) by 86.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,705,195 shares of the biopharmaceutical company’s stock after purchasing an additional 791,485 shares during the period. Acadian Asset Management LLC owned 4.00% of Minerva Neurosciences worth $5,423,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors also recently bought and sold shares of the company. BNP Paribas Arbitrage SA boosted its holdings in shares of Minerva Neurosciences by 226.8% in the third quarter. BNP Paribas Arbitrage SA now owns 8,148 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 5,655 shares during the period. Virtu Financial LLC bought a new position in shares of Minerva Neurosciences in the second quarter worth $39,000. Two Sigma Securities LLC bought a new position in shares of Minerva Neurosciences in the second quarter worth $41,000. Sanders Morris Harris LLC bought a new position in shares of Minerva Neurosciences in the third quarter worth $41,000. Finally, Engineers Gate Manager LP bought a new position in shares of Minerva Neurosciences in the second quarter worth $57,000. 67.42% of the stock is owned by hedge funds and other institutional investors.
NASDAQ:NERV opened at $3.68 on Friday. The firm has a market capitalization of $157.04 million, a price-to-earnings ratio of -6.81 and a beta of 1.50. The business has a fifty day moving average price of $3.37 and a 200-day moving average price of $4.56. Minerva Neurosciences, Inc. has a one year low of $1.81 and a one year high of $15.22.
NERV has been the subject of several research analyst reports. Zacks Investment Research lowered Minerva Neurosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, October 6th. William Blair reiterated a “hold” rating on shares of Minerva Neurosciences in a report on Friday, September 11th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $6.20.
Minerva Neurosciences Profile
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of schizophrenia.
Recommended Story: Beige Book
Want to see what other hedge funds are holding NERV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Minerva Neurosciences, Inc. (NASDAQ:NERV).
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.